期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 14, 期 8, 页码 2012-2015出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2018.1461300
关键词
interleukin-22; interleukin-1; cancer immunotherapy
资金
- international doctoral program i-Target: Immunotargeting of cancer - Elite Network of Bavaria
- Melanoma Research Alliance [409510]
- Marie-Sklodowska-Curie Training Network for the Immunotherapy of Cancer (IMMUTRAIN) - H2020 program of the European Union
- Else Kroner-Fresenius-Stiftung
- German Cancer Aid
- Ernst-Jung-Stiftung
- LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
- Bundesministerium fur Bildung und Forschung VIP+ grant ONKATTRACT
- European Research Council [756017]
Interleukin-22 (IL-22) is a member of IL-10 family of cytokines. IL-22 induces proliferative and anti-apoptotic signaling pathways and production of anti-microbial molecules that enhance tissue regeneration and host defense. IL-22 has also been identified as a cancer-promoting cytokine since deregulation of the IL-22-IL-22R1 system is linked to different cancer entities including lung, breast, gastric, pancreatic and colon cancers. T cells and innate lymphoid cells are the main cellular sources of IL-22. Expression of its specific receptor IL-22R1 is restricted to the non-hematopoietic cells which makes the IL-22-IL-22R1 pathway an attractive target for anti-cancer therapy. For development of such therapies, a better understanding of IL-22 regulation in the tumor microenvironment is needed. We could recently decipher how cancer cells promote IL-22 production by memory T cells via induction of IL-1. Here we will discuss how this knowledge might contribute to developing therapies disregulating the IL-22 pathway for cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据